AveXis (AVXS) PT Raised to $50 at Jefferies on Evidence of Trial Patient Walking

September 19, 2016 7:10 AM EDT
Get Alerts AVXS Hot Sheet
Price: $52.51 -0.19%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade AVXS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on AveXis (NASDAQ: AVXS) to $50.00 (from $42.00) after they found a patient they believe is in the AVXS-101 trial whose parents posted a video of her walking.

While the firm does not have 100% confirmation that this patient is indeed in the AVXS trial, they think there's a strong likelihood that she is in the AVXS-101 trial.

"We believe her achievement to walk is significant given that she a Type 1 SMA baby w/ 2 copy number and would not in any normal circumstance be expected to walk (walking seen in Type 3 SMA). Our finding comes ahead of AVXS' plan to disclose patient data on motor milestones from its PI trial later this year."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $41.72 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Comments

Related Entities

Jefferies & Co, S1

Add Your Comment